Affordable Access

deepdyve-link
Publisher Website

Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study.

Authors
  • Botelho, Stephanie Ferreira1
  • Martins, Maria Auxiliadora Parreiras2
  • Vieira, Liliana Batista3
  • Reis, Adriano Max Moreira2
  • 1 Universidade Federal de Minas Gerais Hospital Risoleta Tolentino Neves, R. das Gabirobas, Belo Horizonte, Brazil. , (Brazil)
  • 2 Universidade Federal de Minas Gerais, Faculdade de Farmácia, Av Antônio Carlos 6627 Pampulha, Belo Horizonte, Brazil. , (Brazil)
  • 3 Universidade Federal de Juiz de Fora, Departamento de Farmácia, Campus Governador Valadares, Universitário 35020220, Governador Valadares, Brazil. , (Brazil)
Type
Published Article
Journal
Journal of clinical pharmacology
Publication Date
Apr 01, 2017
Volume
57
Issue
4
Pages
493–499
Identifiers
DOI: 10.1002/jcph.822
PMID: 27568487
Source
Medline
Keywords
License
Unknown

Abstract

This study investigated postmarketing safety events (PMSEs) for new drugs approved in Brazil and evaluated whether a range of drug characteristics influenced the time between approval and the first PMSE. This retrospective study included new drugs registered between 2003 and 2013 by the National Health Surveillance Agency (ANVISA), which is responsible for medicines approval in Brazil. PMSEs were defined as any drug safety alert or drug withdrawal from the market. The existence of risk evaluation and mitigation strategies (REMS) by the US Food and Drug Administration (FDA) and Brazil were recorded. A Kaplan-Meier survival curve of the period between the date of ANVISA registration and the PMSE was calculated. We found a statistically significant difference between the time to PMSE for drugs with an FDA REMS compared with those without a REMS, with a log rank value (Mantel Cox) of 0.002. There was no association between the time to PMSE and the other drug characteristics investigated. This study demonstrated that the frequency of PMSEs for new drugs approved by ANVISA was statistically associated with the existence of an FDA REMS. The time between approval and first PMSE was shorter for drugs with an FDA REMS, and this finding may contribute to improved awareness of the risk/benefit balance required to ensure continued safe and effective use of new drugs.

Report this publication

Statistics

Seen <100 times